Additional amount of payments receivable per drug or program for regulatory milestone.

No definition available.

Name:	akca_AdditionalAmountOfPaymentsReceivablePerDrugOrProgramForRegulatoryMilestone
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Consideration amount received.

+ References

No definition available.

+ Details

Name:	akca_ConsiderationAmountReceived
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for commercialization milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForCommercializationMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for development milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForDevelopmentMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The maximum amount of payments receivable for regulatory milestones under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_MaximumAmountOfPaymentsReceivableForRegulatoryMilestones
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Milestone payments and royalties payable percentage.

+ References

No definition available.

+ Details

Name:	akca_MilestonePaymentsAndRoyaltiesPayablePercentage
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Milestone payments and royalties retained percentage.

+ References

No definition available.

+ Details

Name:	akca_MilestonePaymentsAndRoyaltiesRetainedPercentage
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

The next potential milestone payment to be earned under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_NextPotentialMilestonePayment
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Period of time before collaboration partner pays royalties on net sales of product after first commercial sale in Brazil, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	akca_PeriodBeforeCollaborationPartnerPaysRoyaltiesOnNetSalesOfProductAfterFirstCommercialSaleInBrazil
Namespace Prefix:	akca_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of separate performance obligations under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix:	akca_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

The amount of consideration the Company is eligible to earn under the collaboration agreement, including any variable consideration.

+ References

No definition available.

+ Details

Name:	akca_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The minimum amount of revenue recognized in Latin America by the collaboration partner before paying royalties.

+ References

No definition available.

+ Details

Name:	akca_RevenueRecognizedByCollaborationPartnerInLatinAmericaBeforePayingRoyalties
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Royalty percentage received on the sales of a drug by a collaboration partner under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_RoyaltyPercentageReceivedOnSalesOfDrug
Namespace Prefix:	akca_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of the sublicense fee paid in common stock.

+ References

No definition available.

+ Details

Name:	akca_SublicenseFeePaidForLicenseOfDrug
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Sublicense fee payable.

+ References

No definition available.

+ Details

Name:	akca_SublicenseFeePayable
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Upfront license fee receivable under license agreement.

+ References

No definition available.

+ Details

Name:	akca_UpfrontLicenseFeeReceivable
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of upfront payments received during the period under the collaboration agreement.

+ References

No definition available.

+ Details

Name:	akca_UpfrontPaymentReceived
Namespace Prefix:	akca_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TransactionTypeAxis=akca_CardiometabolicLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TransactionTypeAxis=akca_TTRLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=akca_IonisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=akca_AkceaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_AKCEAAPOALMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_AKCEAAPOCIIILMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akca_CollaborationAgreementEnteredIntoInJanuary2017WithNovartisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akca_CollaborativeArrangementAndLicensingAgreementEnteredIntoInAugust2018WithPTCTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ConsolidatedEntitiesAxis=akca_AkceaTherapeuticsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_TEGSEDIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_OwnershipAxis=akca_IonisPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=akca_LicenseAgreementWithPfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_TransferOfLicenseOfAKCEAANGPTL3LRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_DevelopmentServicesForAKCEAANGPTL3LRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_DeliveryOfAKCEAANGPTL3LRxAPIMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=akca_AKCEAANGPTL3LRxMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue from Collaboration and License Agreements - Narratives (Details)		1 Months Ended			3 Months Ended
	Aug. 01, 2018 USD ($)	Oct. 31, 2019 USD ($) PerformanceObligation	May 31, 2019 USD ($)	Feb. 28, 2019 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) shares	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($) shares
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue					$ 16,074,000			$ 163,816,000
Cardiometabolic License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicense fee paid			$ 3,000,000
TTR License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicense fee paid			2,400,000
Ionis [Member] \| Akcea [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Sublicense fee payable								$ 75,000,000
Ionis [Member] \| Common Stock [Member] \| Akcea [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of stock (in shares) \| shares								2,837,373
Licensing [Member] \| Akcea [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				$ 150,000,000
AKCEA-APO(a)-L [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum amount of payments receivable for milestones					675,000,000
Maximum amount of payments receivable for development milestones					25,000,000
Maximum amount of payments receivable for regulatory milestones					290,000,000
Maximum amount of payments receivable for commercialization milestones					$ 360,000,000
Royalty percentage received on sales of drug					20.00%
AKCEA-APOCIII-LRx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized from deferred revenue					$ 0			$ 156,200,000
Novartis [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized from deferred revenue					300,000			$ 900,000
Next prospective milestone					25,000,000
Deferred revenue					0	$ 0
PTC Therapeutics [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue						4,000,000	$ 6,000,000
Consideration amount received		$ 4,000,000	$ 6,000,000
PTC Therapeutics [Member] \| Akcea [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional amount of payments receivable per drug for regulatory milestone	$ 4,000,000
Period before PTC pays royalties on net sales of product after first commercial sale in Brazil	12 months
Minimum revenue recognized in Latin America by PTC before paying royalties	$ 10,000,000
PTC Therapeutics [Member] \| TEGSEDI [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue					400,000
PTC Therapeutics [Member] \| TEGSEDI [Member] \| Akcea [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments and royalties retained percentage	40.00%
PTC Therapeutics [Member] \| TEGSEDI [Member] \| Ionis [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments and royalties payable percentage	60.00%
Pfizer Vupanorsen License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized from deferred revenue					600,000
Sublicense fee payable						$ 125,000,000
Issuance of stock (in shares) \| shares						6,873,344
Deferred revenue					$ 700,000	$ 1,300,000
Upfront license fee receivable						250,000,000
Number of separate performance obligations \| PerformanceObligation		3
Upfront payment received						250,000,000
Transaction price						250,000,000
Pfizer Vupanorsen License Agreement [Member] \| Transfer of License of AKCEA-ANGPTL3-LRx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price						245,600,000
Pfizer Vupanorsen License Agreement [Member] \| Development services for AKCEA-ANGPTL3-LRx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price						2,200,000
Pfizer Vupanorsen License Agreement [Member] \| Delivery of AKCEA-ANGPTL3-LRx API [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Transaction price						$ 2,200,000
Pfizer Vupanorsen License Agreement [Member] \| AKCEA-ANGPTL3-LRx [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Maximum amount of payments receivable for milestones		$ 1,300,000,000
Maximum amount of payments receivable for development milestones		205,000,000
Maximum amount of payments receivable for regulatory milestones		250,000,000
Maximum amount of payments receivable for commercialization milestones		850,000,000
Next prospective milestone		$ 75,000,000
Royalty percentage received on sales of drug		20.00%